Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by...
DUBLIN--(BUSINESS WIRE)--The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.This report offers a detailed...
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of...
A number of research firms have changed their ratings and price targets for Adicet Bio (NASDAQ: ACET): 6/27/2023 – Adicet Bio was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating. 6/27/2023 – Adicet Bio was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating. […]
Adicet Bio, Inc. (NASDAQ:ACET – Free Report) Director Steve Dubin bought 5,000 shares of Adicet Bio stock in a transaction on Friday, June 30th. The stock was purchased at an average price of $2.40 per share, with a total value of $12,000.00. Following the completion of the acquisition, the director now directly owns 10,900 shares […]